Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Evofosfamide

Catalog No: tcsc0616

Available Sizes

Size: 2mg

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
918633-87-1

Formula:
$C_9H_{16}Br_2N_5O_4P$

Pathway:
Others

Target:
Others

Purity / Grade:
>98%

Solubility:
DMSO : 94 mg/mL (209.34 mM; Need ultrasonic and warming)

Alternative Names:
TH-302

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Observed Molecular Weight:
449.04

Product Description

Evofosfamide (TH-302) is a **hypoxia**-activated prodrug with **IC_{50}** of 10 μM and 1000 μM in hypoxia (N_2) and normoxia (21% O_2), respectively.

IC50 & Target: Hypoxia-activated prodrug[1]

In Vitro: Evofosfamide (TH-302) induces γH2AX and apoptosis. Evofosfamide displays hypoxia-selective and concentration-dependent cytotoxic activity that is comparable in both p53-proficient and -deficient cells. Treatment with Evofosfamide (TH-302) alone causes an accumulation of G_2/M cells. Inhibition of Chk1 by PF47736 in cells treated with Evofosfamide reduces Evofosfamide (TH-302)-mediated G_2/M arrest under both normoxia and hypoxia[1].

In Vivo: Evofosfamide (TH-302) is a hypoxia-activated prodrug known to activate selectively under the hypoxic conditions commonly found in solid tumors. The mean values of normalized K^{trans} decrease 69.2% for Evofosfamide (TH-302)-treated mice in Hs766t tumors, decrease 46.1% for Mia PaCa-2 tumors and increase 4.9% in SU.86.86 tumors. Both changes for Hs766t and Mia PaCa-2 treatment groups are statistically significant (P[2]. A significant reduction in the hypoxic fraction (HF) to 2.1%±4.7% is seen after 95% oxygen breathing (P2)[3].